Claims
- 1. An isolated protein comprising a polypeptide that is at least 80% identical to a polypeptide selected from the group consisting of:
a) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 65 of SEQ ID NO:2; b) a polypeptide having the sequence of amino acid residue 19 to amino acid residue 65 of SEQ ID NO:2; c) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 65 of SEQ ID NO:2; d) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10; e) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 67 of SEQ ID NO:10; and f) a polypeptide having the sequence of amino acid residue 23 to amino acid residue 67. of SEQ ID NO:2; wherein said polypeptide has cysteine residues corresponding to amino acid residues 33, 40, 45, 55, 62 and 63 of SEQ ID NO:2 or 10.
- 2. An isolated protein of claim 1, wherein the amino acid percent identity is determined using a FASTA program with ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62, with other parameters set as default.
- 3. An isolated protein of claim 1, wherein said protein comprises a polypeptide having the sequence selected from the group consisting of:
a) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10; b) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 67 of SEQ ID NO:10; and c) a polypeptide having the sequence of amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10.
- 4. A polypeptide selected from the group consisting of:
a) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2; b) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2; c) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2; d) amino acid residue. 31 to amino acid residue 64 of SEQ ID NO:2; and e) a polypeptide chosen from SEQ ID NOS:14-72.
- 5. A pharmaceutical composition comprising a polypeptide selected from the group consisting of:
a) a protein according to claim 1;b) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2; c) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2; d) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2; e) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2; and f) a polypeptide chosen from SEQ ID NOS:14-72;
in combination with a pharmaceutically acceptable vehicle.
- 6. An antibody that specifically binds to a protein of claim 1.
- 7. An anti-idiotypic antibody of an antibody which specifically binds to a protein of claim 1.
- 8. An isolated polynucleotide molecule encoding a protein, said polynucleotide molecule consisting of a coding strand and a complementary non-coding strand, wherein said polynucleotide molecule encodes a polypeptide that is at least 80% identical to the amino acid sequence to a polypeptide selected from the group consisting of:
a) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 65 of SEQ ID NO:2; b) a polypeptide having the sequence of amino acid residue 19 to amino acid residue 65 of SEQ ID NO:2; c) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 65 of SEQ ID NO:2; d) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10; e) a polypeptide having the sequence of amino acid residue 21 to amino acid residue 67 of SEQ ID NO:10; and f) a polypeptide having the sequence of amino acid residue 23 to amino acid residue 67 of SEQ ID NO:2; wherein said polypeptide has cysteine residues corresponding to amino acid residues 33, 40, 45, 55, 62 and 63 of SEQ ID NO:2 or 10.
- 9. An isolated polynucleotide molecule according to claim 8, wherein the amino acid percent identity is determined using a FASTA program with ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62, with other parameters set as default.
- 10. An isolated polynucleotide molecule according to claim 8, wherein said polynucleotide molecule remains hybridized following stringent wash conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO:9, or the complement of SEQ ID NO:9.
- 11. An isolated polynucleotide molecule encoding a protein having cysteine residues corresponding to amino acid residues 33, 40, 45, 55, 62 and 63 of SEQ ID NO:10, said polynucleotide molecule consisting of a coding strand and a complementary non-coding strand, wherein said polynucleotide comprises a nucleotide sequence that is at least 80% identical to the sequence of a polynucleotide selected from the group consisting of:
a) a polynucleotide as shown in SEQ ID NO:9 from nucleotide 220 to nucleotide 420; b) a polynucleotide as shown in SEQ ID NO:9 from nucleotide 280 to nucleotide 420; and c) a polynucleotide as shown in SEQ ID NO:9 from nucleotide 286 to nucleotide 420.
- 12. An isolated polynucleotide molecule encoding a protein having cysteine residues corresponding to amino acid residues 33, 40, 45, 55, 62 and 63 of SEQ ID NO:10, said polynucleotide molecule consisting of a coding strand and a complementary non-coding strand, wherein said polynucleotide comprises a nucleotide sequence as shown in SEQ ID NO:11.
- 13. An isolated polynucleotide molecule encoding a polypeptide selected from the group consisting of:
a) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2; b) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2; c) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2; d) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2; and e) a polypeptide chosen from SEQ ID NO:14-72.
- 14. An isolated polynucleotide molecule selected from the group consisting of:
a) nucleotide 88 to nucleotide 189 of SEQ ID NO: 1; b) nucleotide 88 to nucleotide 192 of SEQ ID NO: 1; c) nucleotide 91 to nucleotide 189 of SEQ ID NO: 1; d) nucleotide 91 to nucleotide 192 of SEQ ID NO:1; e) nucleotide 88 to nucleotide 189 of SEQ ID NO:4; f) nucleotide 88 to nucleotide 192 of SEQ ID NO:4; g) nucleotide 91 to nucleotide 189 of SEQ ID NO:4 and h) nucleotide 91 to nucleotide 192 of SEQ ID NO:4.
- 15. An expression vector comprising the following operably linked elements:
a transcription promoter; a DNA segment encoding a polypeptide selected from the group consisting of:
a) a protein of claim 1;b) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2; c) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2; d) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2; e) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2; and f) a polypeptide chosen from SEQ ID NOS:14-72; and a transcription terminator.
- 16. An expression vector according to claim 15, wherein said DNA segment further encodes a secretory signal sequence operably linked to said. protein.
- 17. An expression vector according the claim 16, wherein said secretory signal sequence is selected from the group consisting of:
a) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 18 of SEQ ID NO:2; b) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 20 of SEQ ID NO:2; c) a polypeptide having the sequence of amino acid residue 1 to amino acid residue 20 of SEQ ID NO:10; and d) a polypeptide having. the sequence of amino acid residue 1 to amino acid residue 22 of SEQ ID NO:10.
- 18. A cultured cell into which has been introduced an expression vector according to claim 15;wherein said cell expresses said polypeptide encoded by said DNA segment.
- 19. A method of producing a protein comprising:
culturing a cell into which has been introduced an expression vector according to claim 15;whereby said cell expresses said polypeptide encoded by said DNA segment; and recovering said expressed polypeptide.
- 20. An oligonucleotide probe or primer comprising at least 14 contiguous nucleotides of a polynucleotide of SEQ ID NO: 11 or a sequence complementary to SEQ ID NO: 11.
- 21. A method of treating a microbial-related disease comprising administering to a mammal a therapeutically effective amount of a polypeptide selected from the group consisting of:
a) a polypeptide of SEQ ID NO:2; b) a polypeptide of SEQ ID NO:10; c) a polypeptide chosen from SEQ ID NO:14-72; h) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2; i) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2; j) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2; k) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2; l) amino acid residue 20 to amino acid residue 67 of SEQ ID NO:10 and m) amino acid residue 22 to amino acid residue 67 of SEQ ID NO:10; whereby said polypeptide ameliorates said disease.
- 24. A method of claim 23, wherein said microbial-related disease is associated with the eye.
- 25. A method of claim 24, wherein said microbial-related disease is conjunctivitis.
- 26. A method of claim 23, wherein said microbial-related disease is associated with the ear.
- 27. A method of contraception comprising administering to a mammal a therapeutically effective amount of a polypeptide selected from the group consisting of:
a) a polypeptide of SEQ ID NO:2; b) a polypeptide of SEQ ID NO:10; c) a polypeptide chosen from SEQ ID NOS:14-72; h) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2; i) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2; j) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2; k) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2; l) amino acid residue 20 to amino acid residue 67 of SEQ ID NO:10 and m) amino acid residue 22 to amino acid residue 67 of SEQ ID NO:10.
- 28. A pharmaceutical composition for treating a microbial infection in a mammal, the composition comprising:
a polypeptide comprising a sequence of amino acids selected from the group consisting of:
a) amino acid residue 1 to amino acid residue 65 of SEQ ID NO:2; b) amino acid residue 19 to amino acid residue 65 of SEQ ID NO:2; c) amino acid residue 21 to amino acid residue 65 of SEQ ID NO:2; d) amino acid residue 30 to amino acid residue o63 f SEQ ID NO:2; e) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2; f) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2; g) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2; h) amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10; i) amino acid residue 21 to amino acid residue 67 of SEQ ID NO:10; j) amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10; k) a polypeptide chosen from SEQ ID NOS:14-72; and l) combinations thereof; an antimicrobial agent; and a pharmaceutically acceptable carrier.
- 29. The composition of claim 28 wherein the polypeptide has cysteine residues corresponding to amino acid residues 33, 40, 45, 55, 62 and 63 of SEQ ID NOS:2 or 10.
- 30. The composition of claim 28 wherein the microbial infection comprises at least one microbe selected from the group consisting of a bacteria, an anaerobic organism, a protozoan, a fungus, and a virus.
- 31. The composition of claim 30 wherein the bacteria is gram negative.
- 32. The composition of claim 31 wherein the bacteria is selected from the group consisting of Escherichia, Enterobacter, Klebsiella, Serratia, Citrobacter, Proteus, Salmonella, Shigella, Yersinia, Neisseria, Bacteroides, Haemophilus, Legionella, Vibrio, Brucella, Bordetella, Campylobacter, Burkholderia, Pseudomonas, and combinations thereof.
- 33. The composition of claim 32 wherein Pseudomonas is Pseudomonas aeruginosa.
- 34. The composition of claim 32 wherein Burkholderia is Burkholderia cepacia.
- 35. The composition of claim 30 wherein the bacteria is gram positive.
- 36. The composition of claim 35 wherein the bacteria is selected from the group consisting of Staphylococcus, Streptococcus, Enterococcus, Bacillus, Clostridium, Mycobacterium, Corynebacterium, and combinations thereof.
- 37. The composition of claim 36 wherein Enterococcus is Enterococcus faecium.
- 38. The composition of claim 36 wherein Staphylococcus is Staphylococcus aureus.
- 39. The composition of claim 36 wherein Staphylococcus is Staphylococcus epidermidis.
- 40. The composition of claim 36 wherein Streptococcus is Streptococcus pyogenes.
- 41. The composition of claim 36 wherein Streptococcus is Streptococcus pneumoniae.
- 42. The composition of claim 36 wherein Streptococcus is Streptococcus mutans.
- 43. The composition of claim 30 wherein the anaerobic organism is selected from the group consisting of Actinomyces viscosus, Bacteroides fragilis, Clostridium sporogenes, Corynebacterium acnes, Helicobacter pylori, Porphyromonas gingivalis and combinations thereof.
- 44. The composition of claim 30 wherein the protozoa is Trichomonas foetus.
- 45. The composition of claim 30 wherein the fungus is Candida albicans.
- 46. The composition of claim 28 wherein the mammal is human.
- 47. The composition of claim 28 wherein the antimicrobial agent is selected from the group consisting of antibiotic, antifungal, antiviral, antiprotozoal, and combinations thereof.
- 48. The composition of claim 47 wherein the antibiotic is a beta-lactam.
- 49. The composition of claim 48 wherein the beta-lactam is selected from the group consisting of penicillin, cephalosporin, cephamycin, carbapenem, carbacephem, and monobactam.
- 50. The composition of claim 49 wherein the penicillin is selected from the group consisting of amdinocillin, amoxicillin, ampicillin, azlocillin, bacampicillin, carbenicillin, cloxacillin, cyclacillin, dicloxacillin, floxacillin, methicillin, mezlocillin, nafcillin, oxacillin, penicillin G, penicillin V, piperacillin, sulbactam, tacarcillin, and timentin.
- 51. The composition of claim 49 wherein the cephalosporin is selected from the group consisting of aztreonam, cefmetazole, loracarbef, cefotetan, cefoxitin, ceftriaxone, imipenem, cilastatin, loracarbef, meropenem, cefadroxil, cefazolin, cephalexin, cephalothin, cephapirin, cephradine, cefaclor, cefamandole, cefonicid, ceforanide, cefprozil, cefuroxime, cefdinir, cefixime, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftraxone, and cefepime.
- 52. The composition of claim 49 wherein the cephamycin is selected from the group consisting of cefoxitin, cefotetan, and cefmetazole.
- 53. The composition of claim 49 wherein the carbapenem is imipenem.
- 54. The composition of claim 49 wherein the carbapenem is meropenem.
- 55. The composition of claim 49 wherein the carbacephem is loracarbef.
- 56. The composition of claim 49 wherein the monobactam is carumonam.
- 57. The composition of claim 49 wherein the monobactam is aztreonam.
- 58. The composition of claim 47 wherein the antibiotic is an aminoglycoside.
- 59. The composition of claim 58 wherein the aminoglycoside is selected from the group consisting of butirosin, streptomycin, dihydrostreptomycin, kanamycin, lividomycin, amikacin, tobramycin, gentamicin, netilmicin, neomycin, and paromomycin.
- 60. The composition of claim 47 wherein the antibiotic is a quinolone.
- 61. The composition of claim 60 wherein the quinolone is selected from the group consisting of cinoxacin, nalidixic acid, ofloxacin, levofloxacin, ciprofloxacin, norfloxacin, enoxacin, lomefloxacin, grepafloxacin, trovafloxacin, alatrofloxacin, sparfloxacin, temafloxacin, moxifloxacin, gatifloxacin, and gemifloxacin.
- 62. The composition of claim 47 wherein the antibiotic is a tetracycline.
- 63. The composition of claim 62 wherein the tetracycline is selected from the group consisting of demeclocycline, doxycycline, minocycline, oxytetracycline, and tetracycline.
- 64. The composition of claim 47 wherein the antibiotic is a sulfonamide.
- 65. The composition of claim 64 wherein the sulfonamide is selected from the group consisting of silver sulfadiazine, sodium sulfacetamide, sulfamethoxazole, sulfanilamide, sulfasalazine, sulfisoxazole, trimethoprim, sulfamethoxazole, and triple sulfa.
- 66. The composition of claim 47 wherein the antibiotic is a macrolide.
- 67. The composition of claim 66 wherein the macrolide is selected from the group consisting of azithromycin, clarithromycin, clindamycin, lincomycin, dirithromycin, erythromycin, and troleandomycin.
- 68. The composition of claim 47 wherein the antibiotic is chloramphenicol.
- 69. The composition of claim 47 wherein the antibiotic is bacitracin.
- 70. The composition of claim 47 wherein the antibiotic is chlorhexidine.
- 71. The composition of claim 47 wherein the antibiotic is colistimethate.
- 72. The composition of claim 47 wherein the antibiotic is dapsone.
- 73. The composition of claim 47 wherein the antibiotic is furazolidone.
- 74. The composition of claim 47 wherein the antibiotic is lincomycin.
- 75. The composition of claim 47 wherein the antibiotic is linezolid.
- 76. The composition of claim 47 wherein the antibiotic is nitrofurantoin.
- 77. The composition of claim 47 wherein the antibiotic is clindamycin.
- 78. The composition of claim 47 wherein the antibiotic is trimethoprim.
- 79. The composition of claim 47 wherein the antibiotic is a polymyxin.
- 80. The composition of claim 47 wherein the antibiotic is colistin.
- 81. The composition of claim 47 wherein the antibiotic is a glycopeptide.
- 82. The composition of claim 81 wherein the glycopeptide is vancomycin.
- 83. The composition of claim 47 wherein the antibiotic is quinupristin/dalfopristin.
- 84. The composition of claim 47 wherein the antibiotic is metrbnidazole.
- 85. The composition of claim 47 wherein the antibiotic is rifampin.
- 86. The composition of claim 47 wherein the antibiotic is spectinomycin.
- 87. The composition of claim 28 wherein the antimicrobial agent is a lipopeptide.
- 88. The composition of claim 28 wherein the antimicrobial agent is a cationic peptide.
- 89. The composition of claim 88 wherein the cationic peptide is indolicidin.
- 90. The composition of claim 28 wherein the antimicrobial agent is a lysozyme.
- 91. The composition of claim 28 wherein the antimicrobial agent is lactoferrin.
- 92. The composition of claim 28 wherein the antimicrobial agent is a beta-defensin.
- 93. A pharmaceutical composition for treating a microbial infection in a mammal, the composition comprising:
a polypeptide comprising a sequence of amino acids having at least 95% sequence identity to the sequence of amino acid residues selected from the group consisting of:
a) amino acid residue 1 to amino acid residue 65 of SEQ ID NO:2; b) amino acid residue 19 to amino acid residue 65 of SEQ ID NO:2; c) amino acid residue 21 to amino acid residue 65 of SEQ ID NO:2; d) amino acid residue 30 to amino acid residue 63 of SEQ ID NO:2; e) amino acid residue 31 to amino acid residue 63 of SEQ ID NO:2; f) amino acid residue 30 to amino acid residue 64 of SEQ ID NO:2; g) amino acid residue 31 to amino acid residue 64 of SEQ ID NO:2; h) amino acid residue 1 to amino acid residue 67 of SEQ ID NO:10; i) amino acid residue 21 to amino acid residue 67 of SEQ ID NO:10; j) amino acid residue 23 to amino acid residue 67 of SEQ ID NO:10; k) a polypeptide chosen from SEQ ID NOS:14-72; and l) combinations thereof; an antimicrobial agent; and a pharmaceutically acceptable carrier; wherein the antimicrobial activity of the composition is greater than the antimicrobial activity of the polypeptide and antimicrobial agent alone under similar conditions.
- 94. The composition of claim 93 wherein the polypeptide has cysteine residues corresponding to amino acid residues 33, 40, 45, 55, 62 and 63 of SEQ ID NOS:2 or 10.
- 95. The composition of claim 93 wherein the microbial infection comprises at least one microbe selected from the group consisting of a bacteria, an anaerobic organism, a protozoan, a fungus, and a virus.
- 96. The composition of claim 95 wherein the bacteria is gram negative.
- 97. The composition of claim 96 wherein the bacteria is selected from the group consisting of Escherichia, Enterobacter, Klebsiella, Serratia, Citrobacter, Proteus, Salmonella, Shigella, Yersinia, Neisseria, Bacteroides, Haemophilus, Legionella, Vibrio, Brucella, Bordetella, Campylobacter, Burkholderia, Pseudomonas, and combinations thereof.
- 98. The composition of claim 97 wherein Pseudomonas is Pseudomonas aeruginosa.
- 99. The composition of claim 97 wherein Burkholderia is Burkholderia cepacia.
- 100. The composition of claim 95 wherein the bacteria is gram positive.
- 101. The composition of claim 100 wherein the bacteria is selected from the group consisting of Staphylococcus, Streptococcus, Enterococcus, Bacillus, Clostridium, Mycobacterium, Corynebacterium, and combinations thereof.
- 102. The composition of claim 101 wherein Enterococcus is Enterococcus faecium.
- 103. The composition of claim 101 wherein Staphylococcus is Staphylococcus aureus.
- 104. The composition of claim 101 wherein Staphylococcus is Staphylococcus epidermidis.
- 105. The composition of claim 101 wherein Streptococcus is Streptococcus pyogenes.
- 106. The composition of claim 101 wherein Streptococcus is Streptococcus pneumoniae.
- 107. The composition of claim 101 wherein Streptococcus is Streptococcus mutans.
- 108. The composition of claim 95 wherein the anaerobic organism is selected from the group consisting of Actinomyces viscosus, Bacteroides fragilis, Clostridium sporogenes, Corynebacterium acnes, Helicobacter pylori, Porphyromonas gingivalis and combinations thereof.
- 109. The composition of claim 95 wherein the protozoa is Trichomonas foetus.
- 110. The composition of claim 95 wherein the fungus is Candida albicans.
- 111. The composition of claim 93 wherein the mammal is human.
- 112. The composition of claim 93 wherein the antimicrobial agent is selected from the group consisting of antibiotic, antifungal, antiviral, antiprotozoal, and combinations thereof.
- 113. The composition of claim 112 wherein the antibiotic is a beta-lactam.
- 114. The composition of claim 113 wherein the beta-lactam is selected from the group consisting of penicillin, cephalosporin, cephamycin, carbapenem, carbacephem, and monobactam.
- 115. The composition of claim 114 wherein the penicillin is selected from the group consisting of amdinocillin, amoxicillin, ampicillin, azlocillin, bacampicillin, carbenicillin, cloxacillin, cyclacillin, dicloxacillin, floxacillin, methicillin, mezlocillin, nafcillin, oxacillin, penicillin G, penicillin V, piperacillin, sulbactam, tacarcillin, and timentin.
- 116. The composition of claim 114 wherein the cephalosporin is selected from the group consisting of aztreonam, cefmetazole, loracarbef, cefotetan, cefoxitin, ceftriaxone, imipenem, cilastatin, loracarbef, meropenem, cefadroxil, cefazolin, cephalexin, cephalothin, cephapirin, cephradine, cefaclor, cefamandole, cefonicid, ceforanide, cefprozil, cefuroxime, cefdinir, cefixime, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftraxone, and cefepime.
- 117. The composition of claim 114 wherein the cephamycin is selected from the group consisting of cefoxitin, cefotetan, and cefmetazole.
- 118. The composition of claim 114 wherein the carbapenem is imipenem.
- 119. The composition of claim 114 wherein the carbapenem is meropenem.
- 120. The composition of claim 114 wherein the carbacephem is loracarbef.
- 121. The composition of claim 114 wherein the monobactam is carumonam.
- 122. The composition of claim 114 wherein the monobactam is aztreonam.
- 123. The composition of claim 112 wherein the antibiotic is an aminoglycoside.
- 124. The composition of claim 123 wherein the aminoglycoside is selected from the group consisting of butirosin, streptomycin, dihydrostreptomycin, kanamycin, lividomycin, amikacin, tobramycin, gentamicin, netilmicin, neomycin, and paromomycin.
- 125. The composition of claim 112 wherein the antibiotic is a quinolone.
- 126. The composition of claim 125 wherein the quinolone is selected from the group consisting of cinoxacin, nalidixic acid, ofloxacin, levofloxacin, ciprofloxacin, norfloxacin, enoxacin, lomefloxacin, grepafloxacin, trovafloxacin, alatrofloxacin, sparfloxacin, temafloxacin, moxifloxacin, gatifloxacin, and gemifloxacin.
- 127. The composition of claim 112 wherein the antibiotic is a tetracycline.
- 128. The composition of claim 127 wherein the tetracycline is selected from the group consisting of demeclocycline, doxycycline, minocycline, oxytetracycline, and tetracycline.
- 129. The composition of claim 112 wherein the antibiotic is a sulfonamide.
- 130. The composition of claim 129 wherein the sulfonamide is selected from the group consisting of silver sulfadiazine, sodium sulfacetamide, sulfamethoxazole, sulfanilamide, sulfasalazine, sulfisoxazole, trimethoprim, sulfamethoxazole, and triple sulfa.
- 131. The composition of claim 112 wherein the antibiotic is a macrolide.
- 132. The composition of claim 131 wherein the macrolide is selected from the group consisting of azithromycin, clarithromycin, clindamycin, lincomycin, dirithromycin, erythromycin, and troleandomycin.
- 133. The composition of claim 112 wherein the antibiotic is chloramphenicol.
- 134. The composition of claim 112 wherein the antibiotic is bacitracin.
- 135. The composition of claim 112 wherein the antibiotic is chlorhexidine.
- 136. The composition of claim 112 wherein the antibiotic is colistimethate.
- 137. The composition of claim 112 wherein the antibiotic is dapsone.
- 138. The composition of claim 112 wherein the antibiotic is furazolidone.
- 139. The composition of claim 112 wherein the antibiotic is lincomycin.
- 140. The composition of claim 112 wherein the antibiotic is linezolid.
- 141. The composition of claim 112 wherein the antibiotic is nitrofurantoin.
- 142. The composition of claim 112 wherein the antibiotic is clindamycin.
- 143. The composition of claim 112 wherein the antibiotic is trimethoprim.
- 144. The composition of claim 112 wherein the antibiotic is a polymyxin.
- 145. The composition of claim 112 wherein the antibiotic is colistin.
- 146. The composition of claim 112 wherein the antibiotic is a glycopeptide.
- 147. The composition of claim 146 wherein the glycopeptide is vancomycin.
- 148. The composition of claim 112 wherein the antibiotic is quinupristin/dalfopristin.
- 149. The composition of claim 112 wherein the antibiotic is metronidazole.
- 150. The composition of claim 112 wherein the antibiotic is rifampin.
- 151. The composition of claim 112 wherein the antibiotic is spectinomycin.
- 152. The composition of claim 93 wherein the antimicrobial agent is a lipopeptide.
- 153. The composition of claim 93 wherein the antimicrobial agent is a cationic peptide.
- 154. The composition of claim 93 wherein the cationic peptide is indolicidin.
- 155. The composition of claim 93 wherein the antimicrobial agent is a lysozyme.
- 156. The composition of claim 93 wherein the antimicrobial agent is lactoferrin.
- 157. The composition of claim 93 wherein the antimicrobial agent is a beta-defensin.
REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 09/344,097, filed on Jun. 25, 1999, which is a continuation in part of U.S. patent application Ser. No. 09/150,786, filed on Sep. 10, 1998, which is related to Provisional Applications 60/058,335, filed on Sep. 10, 1997 and 60/064,294, filed on Nov. 5, 1997. Under 35 U.S.C. §119(e)(1), this application claims benefit of said Provisional Applications.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60058335 |
Sep 1997 |
US |
|
60064294 |
Nov 1997 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09636399 |
Aug 2000 |
US |
Child |
10272121 |
Oct 2002 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09344097 |
Jun 1999 |
US |
Child |
09636399 |
Aug 2000 |
US |
Parent |
09150786 |
Sep 1998 |
US |
Child |
09344097 |
Jun 1999 |
US |